These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19268739)

  • 1. Relation of bisphosphonate therapies and risk of developing atrial fibrillation.
    Bunch TJ; Anderson JL; May HT; Muhlestein JB; Horne BD; Crandall BG; Weiss JP; Lappé DL; Osborn JS; Day JD
    Am J Cardiol; 2009 Mar; 103(6):824-8. PubMed ID: 19268739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
    Abrahamsen B; Eiken P; Brixen K
    J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
    Huang WF; Tsai YW; Wen YW; Hsiao FY; Kuo KN; Tsai CR
    Menopause; 2010; 17(1):57-63. PubMed ID: 19680161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of bisphosphonates on the risk of atrial fibrillation.
    Howard PA; Barnes BJ; Vacek JL; Chen W; Lai SM
    Am J Cardiovasc Drugs; 2010; 10(6):359-67. PubMed ID: 21090829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of types of atrial fibrillation in acute coronary syndromes.
    Lau DH; Huynh LT; Chew DP; Astley CM; Soman A; Sanders P
    Am J Cardiol; 2009 Nov; 104(10):1317-23. PubMed ID: 19892044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates and atrial fibrillation: clinical trial data suggest possible link.
    Prescrire Int; 2011 Apr; 20(115):96-7. PubMed ID: 21648212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial fibrillation and bisphosphonate therapy.
    Pazianas M; Compston J; Huang CL
    J Bone Miner Res; 2010 Jan; 25(1):2-10. PubMed ID: 20091928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of alendronate and risk of incident atrial fibrillation in women.
    Heckbert SR; Li G; Cummings SR; Smith NL; Psaty BM
    Arch Intern Med; 2008 Apr; 168(8):826-31. PubMed ID: 18443257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Calcif Tissue Int; 2010 May; 86(5):335-42. PubMed ID: 20309678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporosis treatments and adverse events.
    Solomon DH; Rekedal L; Cadarette SM
    Curr Opin Rheumatol; 2009 Jul; 21(4):363-8. PubMed ID: 19412101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of bisphosphonate therapy in a community setting.
    Feldstein AC; Weycker D; Nichols GA; Oster G; Rosales G; Boardman DL; Perrin N
    Bone; 2009 Jan; 44(1):153-9. PubMed ID: 18926939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
    Du X; Ninomiya T; de Galan B; Abadir E; Chalmers J; Pillai A; Woodward M; Cooper M; Harrap S; Hamet P; Poulter N; Lip GY; Patel A;
    Eur Heart J; 2009 May; 30(9):1128-35. PubMed ID: 19282274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteoporosis and bisphosphonates].
    Zuber MA
    Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
    [No Abstract]   [Full Text] [Related]  

  • 16. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors.
    Crandall MA; Horne BD; Day JD; Anderson JL; Muhlestein JB; Crandall BG; Weiss JP; Osborne JS; Lappé DL; Bunch TJ
    Pacing Clin Electrophysiol; 2009 Aug; 32(8):981-6. PubMed ID: 19659615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.
    Herrera L; Leal I; Lapi F; Schuemie M; Arcoraci V; Cipriani F; Sessa E; Vaccheri A; Piccinni C; Staniscia T; Vestri A; Di Bari M; Corrao G; Zambon A; Gregori D; Carle F; Sturkenboom M; Mazzaglia G; Trifiro G
    Osteoporos Int; 2015 May; 26(5):1499-506. PubMed ID: 25752621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of bisphosphonates in the treatment of osteoporosis.
    Recker RR; Lewiecki EM; Miller PD; Reiffel J
    Am J Med; 2009 Feb; 122(2 Suppl):S22-32. PubMed ID: 19187809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure.
    Frasure-Smith N; Lespérance F; Habra M; Talajic M; Khairy P; Dorian P; Roy D;
    Circulation; 2009 Jul; 120(2):134-40, 3p following 140. PubMed ID: 19564557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.
    Rhee CW; Lee J; Oh S; Choi NK; Park BJ
    Osteoporos Int; 2012 Jan; 23(1):247-54. PubMed ID: 21431993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.